We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

Shire recently announced that the U.S. Food and Drug Administration (FDA) has approved the company’s recombinant von Willebrand factor (rVWF) product VONVENDI®, for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD). The therapy had already been approved for the on-demand treatment and control of bleeding episodes in adults 18 and older who have VWD.

Emicizumab-kxwh (HEMLIBRA, Genentech) was approved for use by the US Food and Drug Administration on November 16, 2017 for individuals with hemophilia A and inhibitors.

NHF's MASAC has issued the latest revision to their most comprehensive treatment document.

The designation is for people with hemophilia A without inhibitors.

Dawn Rotellini

NHF is expanding its work with the bleeding disorders community around the world.

Subscribe to Our Newsletter

Fill in the fields below to receive our email newsletter.